Formulation And Evaluation Of Self Emulsifying Drug Delivery System Of Nevirapine
DOI:
https://doi.org/10.64252/tx6n2r76Keywords:
Nevirapine, Self-emulsifying drug delivery system (SEDDS), Oral bioavailability, Solubility enhancement, Lipid-based formulation, In vitro drug releaseAbstract
A common non-nucleoside reverse transcriptase inhibitor in HIV treatment is nevirapine (NVP). NVP's oral bioavailability is limited by its poor water solubility and high permeability, which classify it as a Class II medication under the Biopharmaceutical Classification System (BCS). Self-emulsifying drug delivery systems, or SEDDS, have drawn interest as a useful strategy for improving the solubility and dissolving of medications that are not highly soluble in water. When gastrointestinal fluids are gently shaken, SEDDS isotropic combinations of oils, surfactants, and cosurfactants form fine oil-in-water emulsions, boosting surface area and promoting absorption. In this study, oleic acid was used as the oil phase, Tween 20 as the surfactant, and PEG600 astheco-surfactant in different ratios to create NVP-loaded SEDDS. Solubility assessment, drug content analysis, Fourier-transform infrared spectroscopy (FT-IR) compatible excipient evaluation, measurement of droplet size and zeta potential, rheological analysis, and in vitro diffusion tests were all part of the pre formulation investigations. In comparison to pure NVP, the improved formulation, which included 32.5% oleic acid, 44.16% Tween 20 and 11.9%PEG 600, demonstrated high drug loading, enhanced solubility, nano sized droplets, and quick self-emulsification. Significantly enhanced release was validated by in vitro diffusion, and formulation robustness was shown by thermodynamic stability testing. Compatibility for encapsulation in firm gelatin capsules was demonstrated by viscosity tests. Overall, NVP's solubility and dissolution were significantly increased by the created SEDDS, which may have improved the drug's oral bioavailability and therapeutic efficacy. For the administration of NVP and other poorly soluble medications, the se results show that SEDDS technology can be a viable substitute, deserving of more research before being used in clinical settings.